Nilsine Partners LLC Purchases New Shares in Neurocrine Biosciences, Inc. $NBIX

Nilsine Partners LLC purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 8,437 shares of the company’s stock, valued at approximately $1,197,000.

A number of other large investors also recently added to or reduced their stakes in the stock. AQR Capital Management LLC lifted its holdings in Neurocrine Biosciences by 83.7% during the third quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock valued at $388,435,000 after purchasing an additional 1,263,633 shares in the last quarter. Norges Bank purchased a new stake in shares of Neurocrine Biosciences during the second quarter worth about $122,278,000. JPMorgan Chase & Co. raised its position in shares of Neurocrine Biosciences by 11.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock worth $664,019,000 after purchasing an additional 468,405 shares during the last quarter. Two Sigma Investments LP acquired a new position in shares of Neurocrine Biosciences during the 3rd quarter worth about $48,791,000. Finally, Adage Capital Partners GP L.L.C. purchased a new position in Neurocrine Biosciences in the 2nd quarter valued at about $42,933,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

NBIX has been the topic of several research analyst reports. Truist Financial lowered their price objective on Neurocrine Biosciences from $169.00 to $140.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Needham & Company LLC reduced their target price on Neurocrine Biosciences from $187.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Mizuho raised their target price on Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, December 12th. BMO Capital Markets lowered their price target on Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating on the stock in a research note on Thursday, February 12th. Finally, Stifel Nicolaus boosted their price target on Neurocrine Biosciences from $183.00 to $188.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.10.

Neurocrine Biosciences Trading Up 0.6%

NBIX opened at $132.56 on Thursday. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $160.18. The firm has a market capitalization of $13.30 billion, a PE ratio of 28.45, a PEG ratio of 0.69 and a beta of 0.35. The firm’s 50-day moving average price is $131.77 and its 200 day moving average price is $139.25.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 EPS for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The business had revenue of $805.50 million during the quarter, compared to analyst estimates of $804.21 million. During the same quarter in the previous year, the company posted $1.69 EPS. The firm’s revenue was up 28.3% on a year-over-year basis. As a group, analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Kyle Gano sold 36,400 shares of the company’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares in the company, valued at $18,632,008.90. This represents a 20.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.80% of the stock is owned by company insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.